Tuberculous meningitis

Area of Science:

• Neurology
• Infectious Diseases
• Public Health

Background:

• Tuberculous meningitis (TBM) is a severe extrapulmonary form of tuberculosis.
• Its incidence and prevalence remain largely unknown, particularly in high-burden countries.
• Children and individuals with Human Immunodeficiency Virus (HIV) are disproportionately affected.

Purpose of the Study:

• To summarize the key aspects of tuberculous meningitis.
• To highlight diagnostic challenges and treatment strategies.
• To emphasize the critical need for prompt intervention.

Main Methods:

• Review of pathological processes including meningeal inflammation, vasculitis, and hydrocephalus.
• Analysis of clinical manifestations such as headache, vomiting, and neurological deficits.
• Discussion of diagnostic criteria involving clinical presentation, neuroimaging, and cerebrospinal fluid analysis.
• Examination of bacteriological confirmation methods: smear, culture, and PCR.

Main Results:

• TBM is characterized by inflammation, exudates, vasculitis, and hydrocephalus.
• Clinical features include headache, vomiting, meningeal signs, focal deficits, and raised intracranial pressure.
• Diagnosis relies on clinical signs, neuroimaging, and CSF analysis (high protein, low glucose, pleocytosis).
• Bacteriological confirmation is essential.
• Mortality and morbidity rates are exceptionally high.
• Corticosteroids improve outcomes, while drug resistance increases mortality.
• Hydrocephalus may necessitate surgical intervention (shunting).

Conclusions:

• Prompt diagnosis and early treatment are crucial for improving outcomes in tuberculous meningitis.
• Treatment typically involves a 6-12 month course of antituberculous drugs, often initiated empirically.
• Corticosteroid use is recommended to reduce mortality.
• Bacillus Calmette-Guérin (BCG) vaccination offers partial protection in children.